Pfizer's new Xeljanz formula powers forward; Boehringer team nabs digital comms award; AbbVie med gets special NHS commission;

> Pfizer ($PFE) said the FDA accepted its application for a new once-daily dose of its JAK inhibitor Xeljanz, as a second-line treatment for rheumatoid arthritis. Release

> Boehringer Ingelheim's Not Just One Disease blog at ASCO 2014 picked up a digital communications prize in London; Ogilvy HealthPR spearheaded the effort. Report

> AbbVie's ($ABBV) Parkinson's disease drug Duodopa won approval from England's National Health Service via a new commissioning policy, which will streamline prescribing; the med was previously only available via a case-by-case funding request. Report

> Gilead Sciences ($GILD) filed for FDA approval for its latest triple-drug therapy for HIV; approval could come as early as this year. Report

> Since its new CMO joined Johnson & Johnson ($JNJ) in 2013, the company has focused on data to tailor its marketing and advertising. Report

And Finally... University of Pennsylvania researchers may have identified how small DNA differences affect the effectiveness and safety of thiazolidinedione meds for diabetes. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.

Analysts are cautiously optimistic Amgen's $13.4 billion purchase of Celgene's psoriasis blockbuster Otezla will pay off.